Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.(Phase 3 study)

Trial Profile

Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.(Phase 3 study)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Zonisamide (Primary)
  • Indications Lewy body disease; Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 06 Apr 2017 According to a Sumitomo Dainippon Pharma media release, an extension study is ongoing.
    • 06 Apr 2017 Primary endpoint has been met. (Efficacy : UPDRS Part III total score), as reported in a Sumitomo Dainippon Pharma media release.
    • 06 Apr 2017 According to a Sumitomo Dainippon Pharma media release, based on the data from this trial company intends to submit a supplemental New Drug Application (sNDA) in Japan for Parkinsonism accompanying DLB in FY2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top